Hasil Pencarian - Chelsie Macedo

  • Menampilkan 1 - 3 hasil dari 3
Perbaiki Hasil
  1. 1
    12 Key pharmacokinetic and pharmacodynamic parameters that correlate with the anti-tumor activity of a bispecific PD-L1 conditional 4–1BB agonist

    12 Key pharmacokinetic and pharmacodynamic parameters that correlate with the anti-tumor activity of a bispecific PD-L1 conditional 4–1BB agonist oleh Quinn Deveraux, Heather Kinkead, Chelsie Macedo, Angelica Sanabria, Garrett Cyprus, Rajay Pandit, James Kalabus, Bryan Becklund, Florian Sulzmaier, John Timmer, Brendan Eckelman, Analeah Heidt

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    722 INBRX-121 is an NKp46-targeted detuned IL-2 with antitumor activity as a monotherapy or in combination with multiple cancer immunotherapy modalities

    722 INBRX-121 is an NKp46-targeted detuned IL-2 with antitumor activity as a monotherapy or in combination with multiple cancer immunotherapy modalities oleh Heather Kinkead, Chelsie Macedo, Angelica Sanabria, Rajay Pandit, Florian Sulzmaier, John Timmer, Brendan Eckelman, Analeah Heidt, Anya Polovina, Nadja Kern, Abrahim Hussain, Sae Jeong Ahn, William Crago

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses

    INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses oleh Jason Ho, Chelsie Macedo, Garrett Cyprus, Rajay Pandit, Anya Polovina, Nadja Kern, Abrahim Hussain, Sae Jeong Ahn, William Crago, Emily Rowell, Florian J Sulzmaier, John C Timmer, Brendan P Eckelman

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: